Abstract: Provided is a use of miRNA-214 inhibitor in inhibiting regulatory T cells (Treg cells). The microRNA-214 (miRNA-214) can promote Treg cells, and can assist tumors in immune escape. The experiments demonstrates that the inhibition of miRNA-214 can inhibit the growth of Treg cells, thus inhibiting the growth of tumors. Therefore, miRNA-214 can be used for developing an anti-tumour drug or a drug inhibiting immune response hyperactivity.

Abstract: The present invention discloses an siRNA that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS siRNA and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS siRNA has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the siRNA of the invention and its vector can form a stable siRNA that functions in a host.

Abstract: The present invention relates to a microparticle comprising a functional microRNA/siRNA and application thereof. Specifically, disclosed is a use of a functional microRNA and/or siRNA, which is used to prepare a composition applied to a mammal. After the composition is applied, the microparticle is formed in a first part in an animal, and transported to a second part, which thereby improves physiological status of the second part or heals a disease of the second part. The second part is different from the first part. The use is beneficial for optimizing a dosing manner of the functional microRNA and/or siRNA.

Abstract: Provided is an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia, and particularly, provided are a method of a tandem expression for siRNA of BTK, and an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia.

Abstract: The present invention relates to an avian influenza virus miRNA and the identification, detection and application thereof. In particular, a kind of specific microRNA, miR-HA-3p, is screened for the first time through detecting the microRNA expression levels in samples of animals with avian influenza. The experiments prove that the miR-HA-3p, as a microRNA marker, can be very effective in detecting avian influenza virus and avian influenza. Furthermore, inhibiting the function of miR-HA-3p can be very effective in relieving symptoms of avian influenza and treating avian influenza. The microRNA revealed in the present invention for the first time can be developed into a detection agent and a therapeutic agent as well as the corresponding kits for the detection and treatment of avian influenza (e.g., H5N1).

Abstract: The invention relates to plants as functional microRNA and/or functional siRNA vehicles, the preparation methods and uses thereof. In particular, disclosed in the present invention are plants or edible portions or extracts thereof as functional microRNA and/or functional siRNA vehicles and uses thereof. Also disclosed is a method for carrying the functional microRNA and/or functional siRNA, comprising the step of orally administering the plants or edible portions or extracts thereof to a subject in need thereof, wherein the plants or edible portions thereof express and carry the functional microRNA and/or functional siRNA vehicles, and the extracts contain the functional microRNA and/or functional siRNA.

Abstract: Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.

Abstract: This invention provides a combination of microRNAs for evaluating the physiological and/or pathological condition of a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of a subject; and a method for evaluating the physiological and/or pathological condition of a subject, wherein the method includes determining all detectable microRNAs stably existing in the serum/plasma of a subject; and a kit for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject.

Abstract: Provided are a new precursor miRNA and the applications in tumor therapy thereof. The precursor miRNA, from 5?- to 3?-end thereof, has the structure represented by formula (I). B1 is an anti-miRNA and/or siRNA to be expressed; B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; C is a sequence with stem-loop structure; A1 and A2 are independently hydrogen or optionally a RNA sequence consisting of 4 to 5 bases. The precursor miRNA can be processed to form an anti-miRNA and/or siRNA in hosts.

Abstract: Provided are a precursor miRNA and application thereof in a tumor treatment. The precursor miRNA from the 5? end to 3? end has a structure presented as formula I: B1 is anti-miRNA-214-5p; B2 is an essentially complementary sequence or a totally complementary sequence to B1, and B2 and C are not complementary; C is a sequence having a stem-loop structure; A1 and A2 are respectively RNA sequences having no or 4-5 bases freely selected bases respectively; the precursor miRNA shown can be processed to form anti-miRNA-214 in a host, and only anti-miRNA-214-5p but not anti-miRNA-214-3p is expressed in the anti-miRNA-214.

Abstract: MicroRNAs are provided for evaluating the physiological and/or pathological condition of a subject; and a kit thereof is provided for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors.

Abstract: Methods, systems, and computer readable media for automated detection of abnormalities in medical images are disclosed. According to a method for automated abnormality detection, the method includes receiving a target image. The method also includes deformably registering to the target image or to a common template a subset of normative images from a plurality of normative images, wherein the subset of normative images is associated with a normal variation of an anatomical feature. The method further includes defining a dictionary using the subset of normative images. The method also includes decomposing, using sparse decomposition and the dictionary, the target image. The method further includes classifying one or more voxels of the target image as normal or abnormal based on results of the sparse decomposition.

Abstract: Provided is non-coded RNA of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof. Also provided is a method of identifying the non-coded RNA of in-vivo pathogen sources. The invention also provided a pharmaceutical composition containing an inhibitor for specifically inhibiting or blocking a RNA sequence and a method to treat a pathogen infectious disease or parasitic disease by administering an inhibitor, which inhibits a non-coding RNA sequence derived from a pathogen in the body of an animal, to an animal subject in need thereof.

Abstract: The present invention provides Salmonella non-coding RNA and the identification and application thereof. In particular, the present invention proves through experiments that a Salmonella bacterium delivers non-coding RNAs (ncRNAs) encoded by the bacterium itself into a host cell, generates milRNAs similar to microRNAs by means of a microRNA splicing system in the cell, regulates the immune system with the milRNAs, and further protects the Salmonella bacterium from being cleared by the host. Adsorbing milRNAs using milRNA inhibitors can effectively inhibit the survival ability of the bacterium in the cell, leading to a reduced vitality of the bacterium. The present invention further provides relevant reagents and methods for effective detection of, treatment to and study on Salmonella bacteria or Salmonella infectious diseases.

Abstract: The present invention relates to a method for modulating miRNA content in living beings and the use thereof, whereof the miRNAs are delivered initiatively and selectively by microparticles/MVs/exosomes to the circulatory system and target cells/tissues to perform various functions. The invention provides a novel combination of molecules that mediates the inter-cellular communication: the miRNAs secreted by cells through cellular MVs. Meanwhile, the present invention also provides a method for preparing cellular MVs entrapping certain miRNAs, and, according to the regulation and modification of gene expression in cells and tissues with the miRNA-entrapping cellular MVs, provides a novel method for modulating miRNA content in living beings, which is effective and adoptable to all cell types.

Abstract: The application discloses a radio frequency identification (RFID) tag reading system, an RFID reading-writing apparatus and an RFID tag reading method. According to an embodiment of the RFID tag reading system, an RFID tag is attached to a side surface of a sample vessel and stores preset information indicating a unique identity of one or more biological samples loaded in the sample vessel. When an RFID reading-writing apparatus and the sample vessel are arranged on a same bench, and a distance between the RFID reading-writing apparatus and the RFID tag is less than or equal to a preset induction distance, the RFID reading-writing apparatus can read the preset information stored in the RFID tag through an induction field which is generated on a side of the RFID reading-writing apparatus and can emit radio frequency signals along a substantially horizontal direction.

Abstract: An isolated plant-functional microRNA or an extract containing said plant-functional microRNA, a preparation method therefor, and an application thereof are provided. The plant-functional microRNA originates from the endogenous microRNA of a plant, is present in a water-soluble and/or fat-soluble extract of said plant, and is capable of regulating non-plant target-genes.

Abstract: The present invention discloses the use of placenta permeable small RNAs, particularly the use of small ribonucleic acids (small RNAs) in the preparation of a medicament comprising the small RNAs as active substances, wherein the medicament is administered to a mother's body directly and the small RNAs enter the fetus through the placenta to play their role in the fetus. Trials have shown that the small RNAs when administered directly to the mother's body in different ways such as oral and intragastric administration can enter the fetus through the placenta to play their role directly in the fetus. The invention provides a novel administration method that can minimize the damage to a fetus.

Abstract: Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.

Abstract: The present invention provides microRNAs for assessing the status of pancreatic cancer in a subject, and provides methods, kits, and biochips for detecting said microRNAs.